In December 2023, Imexpharm was honored as one of the Best Annual Report and Best Corporate Governance Companies, acknowledging its excellence in adopting and implementing best practices in corporate governance and operations, as demonstrated through its comprehensive internal disclosures and compliance with market regulatory standards.
The evaluation by the organizing committee shows that the award-winning Annual Reports and Corporate Governance practices serve as exemplary models for other businesses in the market. Moreover, these achievements provide a foundation for policymakers and regulatory authorities to raise common and detailed standards for managing and operating enterprises, enhancing competitiveness on a national scale.
Imexpharm proudly named among Top 10 Best Corporate Governance Companies
This accolade is a testament to Imexpharm’s commitment to professionalism, transparency, and adherence to international standards and practices in financial reporting, auditing, and corporate governance.
The results of the Listed Companies Awards were announced on December 15 in Cam Ranh, Khanh Hoa. The event aims to evaluate and encourage listed companies to enhance professionalism, transparency, and effective communication in their Annual Reports, Financial Statements, and Sustainability Reports. It also helps assess corporate governance practices based on publicly disclosed information, promoting the adoption of international standards in governance.
Imexpharm has been recognized in the Top 20 Best Annual Reports
According to the organizing committee, this year’s evaluation included 116 annual reports, with 24 from the financial sector and 92 from the non-financial sector.
People's Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, shared: "As the first pharmaceutical companies listed on HCMC stock exchange since 2006, we have pursued the goal of becoming a sustainable, professional, and transparent company in all our activities, especially in corporate governance. This recognition reflects the positive efforts of Imexpharm, strengthening trust among our customers, shareholders, and investors."
"Striving for sustainable development, Imexpharm continuously invests in product quality while ensuring reasonable pricing for patients. Quality remains one of our key strengths, recognized by hospitals, doctors, and patients over the years. To achieve this, we maintain internationally certified production systems, focusing on comprehensive investments in EU-GMP standard factories and other advanced international standards," Ms. Tran Thi Dao added.
Reflecting on the first 11 months of the year, Imexpharm demonstrated remarkable progress despite ongoing domestic economic challenges following two years of COVID-19. In November 2023, the company achieved total revenue of VND 230.3 billion, an increase of 11.9% compared to November 2022. Cumulatively, for the first 11 months of 2023, Imexpharm reported net revenue of VND 1,788.8 billion and pre-tax profit of VND 360.6 billion, marking increases of 23.2% and 36.2%, respectively, compared to the same period in 2022.
With these results, Imexpharm has exceeded its 2023 revenue target by 2.2% and profit target by 3%, as outlined in the Shareholders’ General Meeting. These impressive achievements demonstrate the company’s sustainable and effective growth.
To maintain this momentum, Imexpharm will prioritize effectively managing strategic objectives through the Balanced Scorecard (BSC) framework for each division and accelerating progress toward completing its 2023 goals. The company will also closely monitor production plans across its factories to meet market demands during the year-end season.
Additionally, Imexpharm will manage inventory levels strictly, ensuring optimal stockpiles of finished goods and raw materials for production while meeting market needs. The company will also review its financial plans, including budgets and cash flow, to secure the resources necessary for stable operations in the final quarter and into the upcoming year.